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This paper aims to make suggestions for a small step forward in both
preventative and therapeutic measures against the Coronavirus disease
2019 (COVID 19) pandemic. This targeted strategy consists of using fully
recovered COVID 19 Heroes, that is, brave volunteers, as the source of
antibodies in plasma collected by plasmapheresis, plasma exchange, or
substitution therapy for use in those populations in need of antibody. This
would include use in critically ill COVID 19 patients and, as a preventative
measure, in those at potential risk of infection as no vaccine is yet avail-
able. This would be a small step forward, while we are waiting to produce
an effective, validated vaccine and witnessing increasing testing, self-iso-
lation, contact tracing, tracing which are the two most effective current
strategies [1,2].
In line with this concept, some methodological aspects of the use of
the UVC sterilization of FFP/ cryoprecipitate-depleted FFP or im-
munoglobulins containing neutralizing antibodies for clinical use
against COVID-19 are highlighted. The plasmapheresis procedure is, of
course, particularly targeted to male donors, who consist of about 75 %
of the COVID-19 population and who are able to undergo multiple
double, or even triple plasmapheresis procedures. Moreover, as some of
these donors have already been in an induced-hypercoagulable state
and prone to thrombosis and DVT, this strategy will be partially aimed
at improving their health with the use of citrate based anticoagulants
and removal of high molecular weight viscous components which
contribute to the untoward clinical effects of DVT. Similarly, recipients
getting at least two doses of high affinity antibodies directed against
COVID 19. The recipients of such a derived FFP-product would benefit
from the antibodies which could neutralize the viral antigens even at
very low concentration if present in the early stage [3].
Needless to emphasize that, conceptually, the safety of donors in
such special cases is paramount. An additional bonus to donors is that,
in these authors' experiences, many laboratory haemostatic abnormal-
ities are often seen in critically ill COVID-infected patients, this is
considered to be a very important clinical issue, in view of the high
incidence of thrombotic events observed in this population, some with
kidney failure and a fatal outcome. Repeated targeted plasmapheresis
or plasma exchange of selected COVID-19 positive individuals would
undoubtedly lower their state of hypercoagulability and normalize their
hypercoagulability. So, this practice would be a double-edged sword
with benefits for both donors and recipients alike [4].
Both the plasmapheresis collection process and plasma exchange are
very well accepted clinical procedures in transfusion practice in countries
that are equipped with modern mobile apheresis technologies. Such mo-
bile and fully automated tools, using digital technology, will allow this
well-established practice to be available for use, by either a nurse or
trained phlebotomy technologist who might be able to run 6 donors under
the supervision of a trained skilled clinician even in home care sites.
Therefore, transfusion of plasma or its derived products containing im-
munoglobulin from patients who have fully recovered from COVID-19 will
be an additional intervention to be used for those who are not able to
defend themselves against this pandemic virus, in the absence of the
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relevant vaccine. While early infection is identified by modern and sen-
sitive.
RNA based PCR testing, extensive community testing for levels of
antibody will be required to find patients who will volunteer to help
others by donating plasma. Meanwhile, the current concept of mass
testing by sensitive and reliable PCR methodology, mass testing,
tracking, tracing, testing, and the recently proposed strategy of segre-
gating and isolating the older populations, who are more at risk of
getting fatal infections will be perused with rigour, to reduce the cur-
rent rise in deaths. These strategies are of particular relevance for the
hospital front line staffs and in the home care sections. There is
nevertheless an increase in fatalities in younger populations as this
virus does not recognize age or race and individual variability appears
to matter as to how an individual responds to viral infection and the
possibility of the second wave of infection cannot be totally rule out yet.
Conceptually, the plasmapheresis therapeutic approach is based on
well-established passive immunotherapy, as achieved successfully after
Ebola Virus outbreak. The neutralizing ability of sars cov-2 im-
munoglobulins, that thought to be present in COVID-19 convalescent
plasma, would follow the same principal of the passive immunotherapy.
Moreover, such a therapeutic intervention can be considered as a true
reflection of the precision transfusion concept, consisting of the use of the
right product for the right patient in the right time and the right con-
dition, with no risk but added health benefits to donors and recipients
alike. We would like to emphasize that these individuals will often be at
an elevated risk for thrombosis and VTE, hence an appropriate risk as-
sessment at the same time will be warranted and plasmapheresis dona-
tions, with citrated anticoagulant, would enormously help in lowering
their existing and or induced-hypercoagulability by COVID-19 [4].
In this context, it should be noted that the safety and efficacy of
convalescent COVID-19 plasma as a treatment for COVID-19 is yet to be
validated. However, even as an experimental therapy, in line with the
first principal of all newer bioproducts for transfusion, one needs to be
consistent with ethical and legal safeguards (informed consent of donors
and patients, institutional approval, special labelling as an investiga-
tional product and compliance with applicable regulatory requirements).
Moreover, COVID-19 plasma should be used in the context of an orga-
nized research study designed to determine its safety and efficacy in
comparison with standard of care or other therapeutic interventions.
Even if used empirically it is vital to ensure monitoring of patient out-
comes including clinical and laboratory indicators of safety and efficacy
to optimized/ maximize the knowledge that might be gained [5].
Currently, the collection process and transfusion of plasma derived
from patients who have fully recovered from COVID-19 is of wide
spread interest both nationally and internationally as the development
of the infection and its propagation are pandemic. Therefore, using
neutralizing anti- SARS COV-2 immunoglobulins that are present in
COVID-19 convalescent plasma as such or after isolating its more en-
riched immunoglobulin portion is logically an interesting targeted
therapeutic approach, acting on the same foundation of the well-es-
tablished concept of passive immunotherapy.
Transfusion services and many other establishments with the ap-
propriate skills in handling therapeutic apheresis have the appropriate
know how to effectively perform this procedure and in fact such a
multiple horse trials on 6500 volunteers is planned and begun in the
early May 2020 to overcome COVID-19.
Another validated strategic safety measure that could be im-
plemented for the quality improvement of plasmapheresis FFP and its
derived cryosupernatant, is based on pathogen reduction with UVC or
others available technologies. This provides additional quality assur-
ance even if low grade any others infectious viral agents might present,
hence will be eliminated. This procedure has been validated and uses
the principle of sterilization to kill both viruses and bacteria with a very
good safety record. Alternatively, the application affinity column de-
rived specific antibodies might prove useful as an essential part of a
relevant clinical research development for purer and safer products.
In respect to total quality management of the whole process from
donor to recipient, several key points of total quality management need to
be addressed:
1] The collection and retention of blood specimens from both donors
and recipients (pre- and post-treatment) to permit retrospective
determination of the characteristics of an effective product and
dosage regimen, as well as the characteristics of patients most likely
to benefit from this intervention.
2] The collection of convalescent plasma only by apheresis in order to
avoid unnecessary loss of red cells in the donor and to optimize the
volume of plasma that can be generated for investigational use.
Double plasmapheresis technologies and even triple procedures can
be applied under continual supervision, if required and donor con-
ditions permit.
3] The suitability criteria of COVID-19 convalescent plasma prepared
from whole blood by component separation and considered for in-
vestigational use, if not clinically needed for general patient care.
Transfusion of whole blood to provide convalescent plasma as a
general rule should be avoided unless use of whole blood is clini-
cally indicated.
Moreover, from both laboratory and clinical stand points, several
other key items should be taken into consideration as critical pre-
parative and therapeutic modalities, embodying: a.] The eligibility
of convalescent COVID-19 individuals to donate whole blood or
plasma with the following essential requirements; b.] Confirmation
of previous infection with SARS-CoV-2 by a record of a validated
diagnostic test at the time of illness; c.] An interval of at least 14
days after full recovery; d.] A standard selection criterion for whole
blood or plasma donation according to local requirements and
standard operational procedures; e.] To avoid the risk of Transfusion
Related Acute Lung Injury (TRALI) preference should be given to the
use of plasma from male donors or from female donors who have
never been pregnant including having abortions. This measure is
now well-established to dramatically lower the possibility of the
presence in plasma of antibodies to HLA or granulocyte antigens
that cause TRALI and appear to occur within 6 h after transfusion of
the implicated plasma; f.] The assessment of hypercoagulability,
which is of particular relevance to patients with COVID-19, should
be fully assessed.
4] It is essential that pre-screening and pre-donation testing of con-
valescent COVID-19 donors’ recovery from COVID-19 infection
should be confirmed; a.] Physical examination of the donor to es-
tablish good health including the absence of fever and respiratory
symptoms; b.] If plasma is collected prior to 28 days after full re-
covery from illness, then confirmation of the resolution of the in-
fection should be obtained through demonstration of two non-re-
active Nucleic Acid Tests for SARS-CoV-2 performed at an interval of
at least 24 h on nasopharingeal swabs; c.] Viral in-activation of
convalescent plasma is encouraged to address residual risks of
known transfusion transmissible viruses in an experimental product;
d.] The approximate date of COVID-19 infection, history of symp-
toms, treatments received and date of resolution of all symptoms
should be documented and traceable; e.] The total and neutralizing
titers of anti-SARS-CoV-2 antibodies determined as part of product
characterization before use. Furthermore, donor blood/serum/
plasma samples should be saved and frozen at −80 °C f or retro-
spective testing and further scientific investigations.
5] It is also essential that the main criteria for collection of COVID-19
plasma should be fully documented: a.] Performed in certified blood
establishments (or under exceptional circumstances, hospitals and
other health care facilities routinely engaged in performing whole
blood collection with plasma separation and/or apheresis proce-
dures) by appropriately trained staff; b.] Use only of legally
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approved blood collection or plasmapheresis equipment under
standard operating procedures; c.] Supervision of the collection
process by trained staff; d.] Volume of plasma to be collected: at
least 200–600 mL (without anticoagulant) based on the procedure
and regulatory limits; e.] Plasma units intended for use, as con-
valescent plasma should be clearly labelled. The first plasma dona-
tion can be followed by further donations at a frequency compliant
with local regulations and taking into account the health status of
the donor (in many jurisdictions the interval between apheresis
plasma donations of 600 mL or more should not be less than 7 days
and that between whole blood donations should be at least eight
weeks).
6] Post-donation treatment of plasma record keeping: a.] Where fea-
sible, pathogen inactivation of plasma using a licensed technology is
highly desirable to ensure the current strategies are strictly in place to
effectively optimize the current practices that are in use in some
European establishments. This is an essential regulatory requirement
to control the residual risks of transfusion transmitted infectious
diseases and to allay concern about possible super infections with
SARS COV-2. This is a controversial point since pathogen in activa-
tion cannot be performed in all transfusion services, therefore lim-
iting the widespread use of this treatment modality, despite being
available in many modern establishments and existing even in some
hospitals. b.] Freezing as soon as possible at −30 °C or preferably
colder and stored frozen until administration; c.] Convalescent
plasma collected from donors who do not fulfil post-COVID-19 suit-
ability criteria for blood donation should be stored separately from
other conventional FFP; d.] Plasma sample aliquots should be taken
for archiving at −80 ° C and future potential scientific investigations.
7] Need for implementing additional recommendations for plasma
transfusion: a.] To follow standard procedures and recommendations
for thawing and transfusion of plasma; b.] It is crucial to ensure ABO
compatibility between the donor and the recipient; c.] Transfusion of
plasma from at least two donors may be therapeutically beneficial to
achieve a more effective immune protection from delivery of diverse
antibodies; d.] In the absence of published peer-reviewed reports of
transfusion of convalescent COVID-19 plasma, patients could receive
an initial dose of 200 mL, followed by one or two additional doses of
200 mL according to disease severity and tolerance of the infusions, e.]
Further information on blood/serum/plasma samples of the recipient
prior to and after transfusion should be taken for future potential sci-
entific investigations. Details can be found in the following WHO
document at http://www.who.int/bloodproducts/brn).
Another highly important issue that needs to be highlighted and
emphasized is plasmapheresis in immune-compromised patients parti-
cularly in cases of haematological malignancy. Since morbidity and
mortality associated with coronavirus are highest in the elderly and in
individuals with underlying co-morbidities, it would be of great interest
to identify the most susceptible disease categories for COVID-19 in-
fection with the aim of proposing specific therapeutic interventions. In
this context, with nearly 50,000 hematopoietic cell transplantations
(HSCT) carried out annually, patients who are actively undergoing a
HSCT, or those who survived HSCT with compromised immune systems
make up a large population of susceptible patients in which COVID-19
infection may lead to severe pulmonary distress and could be fatal [6].
Moreover since COVID 19-related pneumonia is mediated by hyper
activation of effector T cells and excessive production of inflammatory
cytokines, such as IL-6, IL-1, interferon-gamma, and TNF. This in-
flammatory process may cause a pathological process that leads to
plasma leakage, vascular permeability, and disseminated intravascular
coagulation. This reaction, called “cytokine storm” is a life-threatening
complication of COVID 19 infection. The immunocompromised status
associated with haematological malignancies may enhance the risk of
bacterial sepsis and COVID-19 and other viral infections [7].
Based on the above, it might be postulated that either the preventive
or the therapeutic use of convalescent plasma may be beneficial in these
patient subcategories, possibly mitigating the impact of COVID-19.
However, well-designed clinical trials are needed to clarify this point.
An Italian study has recently started (called “the Italian Haematology
Alliance”) with the main goal of assessing the incidence and potential
predictive parameters of mortality of COVID-19 in patients with hae-
matological malignancies.
Finally, we believe that the suggested protocol of targeted plasma-
pheresis of volunteer recovered COVID-19 patients constitutes a fea-
sible, well-established and effective therapeutic modality for the
treatment of critically ill patients with severe respiratory distress syn-
drome or septic shock in COVID-19 infected patients. The phase of the
disease in which this treatment modality may be most beneficial is still
a matter of debate (early vs intermediate-late stages of the cytokine
storm reaction phase associated with acute respiratory distress syn-
drome (ARDS) or other severe disease complications). Moreover, as
highlighted above, these patients who often present with some la-
boratory abnormalities and a high incidence of thrombosis, some fatal,
will benefit from intervention as their hypercoagulable states will im-
prove and normalized. The added process of sterilization of the plasma
would make it even safer in line with the use of the best available
therapy. We also support the possibility of using on- line affinity col-
umns for removing either the COVID 19 virus itself or its antibodies
from the circulation of donors or patients. This process has been re-
cently successfully achieved for haemophilia B patients, with a very
high titter of antibodies to Factor IX in Malmo Sweden. This approach
could be used for COVID patients with various matrixes to selectively
remove the antigen or the antibodies, according to need and the column
could be subsequently desorbed to obtain purer substances for ster-
ilisation and intravenous or intramuscular injections. In fact, a capture
ELISA, with a plate coated with recombinant ACE-2, or its complexes
with S- Protein or its S1 subunit, as a specific receptor, could be de-
signed for capturing possible allo- or autoantibodies present in COVID
19 patients, especially those with delayed severe complications. This
would allow measurement of the kinetics of these antibodies during the
pathological evolution. If present, these antibodies are expected to be
alloantibodies, induced by the association of the viral protein. A similar
design could be constructed on an affinity column matrix to capture
antibodies or antigens as required either in the circulation or from FFP-
derived from COVID-19 plasma. Nevertheless, in practice, what we
need urgently is not easily matched with what we want [8].
Based on the concept of plasmapheresis of recovered volunteer
COVID-19 patients we believe this is an attractive achievable project,
which will benefit the targeted donors and the targeted recipients until
a proper effective vaccine is developed and validated. Such activities
should be used along with the current efforts in self-discipline and self-
isolation already in place to reduce the impact and the ever-growing
rate of infection in this crisis, which is paralyzing the economy and
having major impacts on the health of the international community at
large, beyond imaginable limits. There are, in life, many challenges to
overcome but, the present crisis is beyond comprehension, and only by
joining forces in a team effort we can turn these challenges into op-
portunities.
In conclusion, this project is only one small step forward in an
overall, difficult task but it is achievable with due perseverance and
hope. The single message to convey to all scientific communities from
this commentary is to “isolate, isolate, isolate” and to “track, trace and
treat” the population at risk or with potential risks of thrombosis and to
collect the precious FFP to be used for the population in most need
during this pandemic outbreak of coronavirus disease. This approach
involving both the patients and donors health care could be considered
as a double-edged sword with benefits to both patients and donors alike
in this pandemic. Specific recommendations for a standardized pre-
paration, and an optimal use of convalescent plasma at a global level
are needed for COVID-19 patients. These proposals will be helpful in
designing future clinical trials in this area of investigation.
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The use of convalescent blood products with the goal of achieving
passive immunity is not new and was proposed by WHO as one early
option for treating patients with Ebola virus disease. This commentary
on various applications of COVID-19 convalescent plasma and its de-
rived bioproducts with the use of newer technological options that
could theoretically be considered when there is a need to rely on the
most practical therapeutic options are warranted subsequent to ap-
propriate validation programmes. In countries without access to ad-
vanced blood-processing technologies, the choice may initially be re-
stricted to convalescent plasmapheresis using modern apheresis tools
that provide leucoreduced and cell free plasma in a close system that
could be used to treat patients against COVID-19, if the realistic con-
tents of antibody potency are established by testing. The use of at least
two units from two different individuals and /or even preparation of
minipool immunoglobulins containing antibodies from various in-
dividuals would be a preferred realistic option to be considered. In
technologically advanced countries, additional options for pathogen
inactivated and sterilised convalescent plasma or blood products such
as immunoglobulins to COVID 19, including virally inactivated mini-
pool plasma, as it is in current practice for both plasma and platelet
concentrate or a fractionated immunoglobin-derived from either online
or indirectly derived affinity column or others existing operationally
practicable procedures with good or superior safety records could be
used with success subsequent to appropriate validation programs to
established the dosage and clinical trials for establishing the best
practice.
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